[go: up one dir, main page]

PE20151664A1 - Un polipeptido receptor del factor de crecimiento de fibroblasto soluble 3 (fgr3) para el uso en la prevencion o tratamiento de trastornos de retraso de crecimiento esqueletico - Google Patents

Un polipeptido receptor del factor de crecimiento de fibroblasto soluble 3 (fgr3) para el uso en la prevencion o tratamiento de trastornos de retraso de crecimiento esqueletico

Info

Publication number
PE20151664A1
PE20151664A1 PE2015001353A PE2015001353A PE20151664A1 PE 20151664 A1 PE20151664 A1 PE 20151664A1 PE 2015001353 A PE2015001353 A PE 2015001353A PE 2015001353 A PE2015001353 A PE 2015001353A PE 20151664 A1 PE20151664 A1 PE 20151664A1
Authority
PE
Peru
Prior art keywords
prevention
treatment
fgr3
growth factor
skeletal
Prior art date
Application number
PE2015001353A
Other languages
English (en)
Inventor
Elvire Gouze
Original Assignee
Inst Nat Sante Rech Med
Univ Toulouse 3 Paul Sabatier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Univ Toulouse 3 Paul Sabatier filed Critical Inst Nat Sante Rech Med
Publication of PE20151664A1 publication Critical patent/PE20151664A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invencion se relaciona al tratamiento o prevencion del trastorno de retraso del crecimiento esqueletico, en particular una enfermedad esqueletica, desarrollado por pacientes que muestran activacion incrementada anormal del receptor de factor de crecimiento de fibroblastos 3 (FGFR3), en particular por expresion de mutante activado prolongado de FGFR3. Mas particularmente, la presente invencion se relaciona a un FGFR3 soluble para el uso en el tratamiento o prevencion de acondroplasia
PE2015001353A 2013-01-16 2014-01-16 Un polipeptido receptor del factor de crecimiento de fibroblasto soluble 3 (fgr3) para el uso en la prevencion o tratamiento de trastornos de retraso de crecimiento esqueletico PE20151664A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2013/001480 WO2014111744A1 (en) 2013-01-16 2013-01-16 A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders

Publications (1)

Publication Number Publication Date
PE20151664A1 true PE20151664A1 (es) 2015-11-28

Family

ID=48289519

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015001353A PE20151664A1 (es) 2013-01-16 2014-01-16 Un polipeptido receptor del factor de crecimiento de fibroblasto soluble 3 (fgr3) para el uso en la prevencion o tratamiento de trastornos de retraso de crecimiento esqueletico

Country Status (19)

Country Link
US (5) US20150344855A1 (es)
EP (2) EP3736285A1 (es)
JP (3) JP2016506914A (es)
KR (3) KR20160002681A (es)
CN (1) CN105121464B (es)
AU (2) AU2013373679A1 (es)
CA (2) CA2898415A1 (es)
DK (1) DK2945967T3 (es)
EA (2) EA201591324A1 (es)
ES (1) ES2796743T3 (es)
HU (1) HUE049556T2 (es)
IL (2) IL239810A0 (es)
MX (2) MX372787B (es)
PE (1) PE20151664A1 (es)
PL (1) PL2945967T3 (es)
PT (1) PT2945967T (es)
SG (2) SG11201505488XA (es)
SI (1) SI2945967T1 (es)
WO (2) WO2014111744A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201591324A1 (ru) 2013-01-16 2016-01-29 Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль) Полипептид растворимого рецептора 3 фактора роста фибробластов (fgr3) для применения с целью предотвращения или лечения нарушений, связанных с замедлением роста скелета
JP6948945B2 (ja) 2015-01-07 2021-10-13 ファイザー・インク 骨格成長障害を治療するための可溶性ｆｇｆｒ３デコイ
KR101894021B1 (ko) * 2016-04-25 2018-08-31 장부다 Vr 공간에서 컨텐트를 제공하는 방법, 디바이스 및 기록매체
KR20220122762A (ko) 2016-07-07 2022-09-02 화이자 인코포레이티드 가용성 섬유아세포 성장 인자 수용체 3(sfgfr3) 폴리펩티드 및 이의 용도
KR20200103621A (ko) * 2017-09-20 2020-09-02 화이자 인코포레이티드 가용성 섬유아세포 성장 인자 수용체 3(sfgfr3) 폴리펩타이드를 사용하는 비정상적 내장 지방 침착의 치료
CN108410803B (zh) * 2018-03-28 2019-02-05 湖南源品细胞生物科技有限公司 一种诱导脂肪干细胞成软骨分化的培养方法和培养液
CN110272900B (zh) * 2019-04-19 2024-03-26 中国人民解放军陆军军医大学 用于制备骨骼发育异常猪模型的sgRNA及其应用
WO2022106976A1 (en) 2020-11-18 2022-05-27 Pfizer Inc. Stable pharmaceutical formulations of soluble fgfr3 decoys
JP2022184798A (ja) 2021-06-01 2022-12-13 ファイザー・インク ｓＦＧＦＲ３ポリペプチドを生産するための細胞培養方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308236D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Dna vectors
CA2224229A1 (en) 1995-06-12 1996-12-27 Yeda Research And Development Co., Ltd. Fgfr3 as a marker for mesenchymal skeletal progenitor cells
US7067144B2 (en) 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
US7598055B2 (en) 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
AU7684201A (en) 2000-06-28 2002-01-08 Glycofi Inc Methods for producing modified glycoproteins
US7625756B2 (en) 2000-06-28 2009-12-01 GycoFi, Inc. Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
US7863020B2 (en) 2000-06-28 2011-01-04 Glycofi, Inc. Production of sialylated N-glycans in lower eukaryotes
CA2432257A1 (en) * 2000-12-18 2002-06-27 Gene Logic, Inc. Treatment of bone disorders by modulation of fgfr3
IL142118A0 (en) 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
JP2005500034A (ja) 2001-06-20 2005-01-06 プロション バイオテク リミテッド 受容体型タンパク質チロシンキナーゼ活性化を遮断する抗体、そのスクリーニング方法、及びその使用
BRPI0203172B8 (pt) * 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
JP4252746B2 (ja) * 2001-10-05 2009-04-08 一和 中尾 軟骨無形成症治療剤
JP2003104908A (ja) * 2001-09-28 2003-04-09 Ichikazu Nakao 軟骨無形成症治療剤
US7332299B2 (en) 2003-02-20 2008-02-19 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes
IL156495A0 (en) * 2003-06-17 2004-01-04 Prochon Biotech Ltd Use of fgfr3 antagonists for treating t cell mediated diseases
EP1718756B1 (en) 2004-02-24 2011-11-16 Allergan, Inc. Botulinum toxin screening assays
DE602006010874D1 (de) * 2005-07-22 2010-01-14 Five Prime Therapeutics Inc Zusammensetzungen und verfahren zur behandlung von krankheiten mit fgfr-fusionsproteinen
CA2655504A1 (en) 2006-06-15 2007-12-21 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
WO2008038287A2 (en) 2006-09-28 2008-04-03 Hepacore Ltd. N-terminal fgf variants having increased receptor selectivity and uses thereof
PE20081250A1 (es) 2006-11-28 2008-10-07 Centelion FUSIONES Fc CON RECEPTOR PARA FGF SOLUBLE MODIFICADAS, CON ACTIVIDAD BIOLOGICA MEJORADA
WO2008133873A2 (en) * 2007-04-25 2008-11-06 Aveo Pharmaceuticals, Inc. Fgf-binding fusion proteins
US8426396B2 (en) 2008-01-08 2013-04-23 Shriners Hospitals For Children Treatment for achondroplasia
EP2313435A4 (en) 2008-07-01 2012-08-08 Aveo Pharmaceuticals Inc FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) BINDING PROTEINS
US8338569B2 (en) 2008-08-04 2012-12-25 Five Prime Therapeutics, Inc. FGFR extracellular domain acidic region muteins
TWI381848B (zh) 2008-10-20 2013-01-11 Imclone Llc 抗纖維母細胞生長因子受體-3 (fgfr-3) 抗體及包含其之醫藥組合物
CN104788564A (zh) 2009-03-25 2015-07-22 健泰科生物技术公司 抗-fgfr3抗体及其使用方法
CN101585866B (zh) * 2009-07-02 2011-10-05 中国人民解放军第三军医大学野战外科研究所 调节fgfr3活性的多肽及其筛选方法和应用
US8445445B2 (en) 2009-09-15 2013-05-21 Five Prime Therapeutics, Inc. Method of promoting hair growth using FGFR4 extracellular domains
EP2498799B1 (en) 2009-11-13 2016-08-17 Five Prime Therapeutics, Inc. Use of fgfr1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in fgfr2
WO2011084711A2 (en) 2009-12-17 2011-07-14 Five Prime Therapeutics, Inc. Hair growth methods using fgfr3 extracellular domains
JP2013517282A (ja) 2010-01-14 2013-05-16 イェール ユニバ−シティ− 受容体チロシンキナーゼ（ｒｔｋ）のインヒビターおよびその使用方法
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
AU2011350066A1 (en) * 2010-12-27 2013-07-11 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
CN102219860B (zh) 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 FGFR-Fc融合蛋白及其用途
EA030440B1 (ru) 2011-10-24 2018-08-31 Галозим, Инк. Сопровождающая диагностика для терапии антигиалуронановым агентом и способы ее применения
FR2984325A1 (fr) 2011-12-14 2013-06-21 Sanofi Sa Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique
CN104797936B (zh) 2012-07-24 2017-11-24 纽约市哥伦比亚大学理事会 融合蛋白及其方法
BR112015001724A2 (pt) 2012-07-27 2018-04-03 Genentech Inc métodos de tratamento de condições relacionadas a fgfr3
EP4223770A3 (en) 2012-11-05 2023-10-18 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
EA201591324A1 (ru) 2013-01-16 2016-01-29 Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль) Полипептид растворимого рецептора 3 фактора роста фибробластов (fgr3) для применения с целью предотвращения или лечения нарушений, связанных с замедлением роста скелета
SG10201806108TA (en) 2014-01-24 2018-08-30 Ngm Biopharmaceuticals Inc Binding proteins and methods of use thereof
JP6948945B2 (ja) 2015-01-07 2021-10-13 ファイザー・インク 骨格成長障害を治療するための可溶性ｆｇｆｒ３デコイ
KR20220122762A (ko) 2016-07-07 2022-09-02 화이자 인코포레이티드 가용성 섬유아세포 성장 인자 수용체 3(sfgfr3) 폴리펩티드 및 이의 용도
KR20200103621A (ko) 2017-09-20 2020-09-02 화이자 인코포레이티드 가용성 섬유아세포 성장 인자 수용체 3(sfgfr3) 폴리펩타이드를 사용하는 비정상적 내장 지방 침착의 치료

Also Published As

Publication number Publication date
US20150344855A1 (en) 2015-12-03
US11814654B2 (en) 2023-11-14
CA2898415A1 (en) 2014-07-24
JP2016506914A (ja) 2016-03-07
EP2945967A1 (en) 2015-11-25
JP2019107006A (ja) 2019-07-04
EA201591324A1 (ru) 2016-01-29
SG11201505140XA (en) 2015-07-30
WO2014111467A1 (en) 2014-07-24
JP2016506912A (ja) 2016-03-07
AU2013373679A1 (en) 2015-08-13
ES2796743T3 (es) 2020-11-30
IL239810A0 (en) 2015-08-31
HUE049556T2 (hu) 2020-09-28
PT2945967T (pt) 2020-05-28
HK1217959A1 (zh) 2017-01-27
KR20160002681A (ko) 2016-01-08
EP3736285A1 (en) 2020-11-11
WO2014111744A1 (en) 2014-07-24
MX2019013857A (es) 2020-01-20
US20200199545A1 (en) 2020-06-25
PL2945967T3 (pl) 2020-11-16
DK2945967T3 (da) 2020-07-13
AU2014206844A1 (en) 2015-07-16
SI2945967T1 (sl) 2020-10-30
EP2945967B1 (en) 2020-04-15
CN105121464B (zh) 2021-05-07
US20210032607A1 (en) 2021-02-04
SG11201505488XA (en) 2015-08-28
KR20150122136A (ko) 2015-10-30
KR102249454B1 (ko) 2021-05-07
US10724014B2 (en) 2020-07-28
JP6995069B2 (ja) 2022-02-04
IL239996A0 (en) 2015-08-31
US20210032608A1 (en) 2021-02-04
CN105121464A (zh) 2015-12-02
US20150353624A1 (en) 2015-12-10
KR20210054026A (ko) 2021-05-12
EA201591055A1 (ru) 2016-04-29
MX2015009142A (es) 2015-11-06
MX372787B (es) 2020-07-03
US11702642B2 (en) 2023-07-18
CA2896978A1 (en) 2014-07-24

Similar Documents

Publication Publication Date Title
PE20151664A1 (es) Un polipeptido receptor del factor de crecimiento de fibroblasto soluble 3 (fgr3) para el uso en la prevencion o tratamiento de trastornos de retraso de crecimiento esqueletico
CO2019013707A2 (es) Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson
CY1121675T1 (el) Διαμορφωτες υποδοχεων nmdα σπeipο-λακταμης και χρησεις αυτων
CY1121203T1 (el) Θεραπευτικες χρησεις της εμπαγλιφλοζινης
CL2018000039A1 (es) Derivados de oxopiridina sustituidos
MX2017014375A (es) Moduladores del ccr2.
CY1121170T1 (el) Νεες ενωσεις ως ρυθμιστες πρωτεϊνικων κινασων
CL2015002485A1 (es) Uso de agonistas de receptor de péptido formilo 2 para tratar enfermedades inflamatorias oculares
DOP2017000097A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
PH12016501966B1 (en) Compounds and compositions as toll-like receptor 7 agonists
CL2015002123A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
PH12015501598A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
CR20160093A (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub aguda o cronica
MX2015009778A (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
CL2015002434A1 (es) Moduladores benzoimidazol-2-il pirimidinas del receptor h4 de histamina.
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
MX390084B (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
BR112016012840A2 (pt) Derivado de pirimidina e fonte de ácido graxo para uso no tratamento de prisão de ventre
CL2016000019A1 (es) Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión.
UY35359A (es) 7-OXO-PIRIDO[2,3-d]PIRIMIDINAS SUSTITUIDAS Y MÉTODOS DE USO
MX2022000203A (es) Composiciones de liberacion sostenida de endoxifeno.
ECSP16060194A (es) Formas de dosificación farmacéuticas
UY33529A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias?
CL2016002321A1 (es) Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios.
MX2017013879A (es) Composiciones que comprenden anakinra.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal